Novo Nordisk Expands Manufacturing with Fresh Acquisitions
Deal News | Dec 11, 2024 | EIN
The European Commission has approved Novo Holdings' acquisition of Catalent, which will subsequently facilitate the sale of three of Catalent's manufacturing sites to Novo Nordisk. These sites are located in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana, contributing significantly to Novo Nordisk's strategy to expand its drug manufacturing capabilities. Novo Nordisk is paying $11 billion for these sites, which employ over 3,000 personnel specialized in the sterile filling of drugs. The acquisition aims to bolster Novo Nordisk's existing supply network, offering strategic flexibility to serve more individuals with diabetes and obesity. Separately, Novo Nordisk is acquiring Novavax's manufacturing facility in the Czech Republic for $200 million. The facility comprises a state-of-the-art recombinant protein production unit, and this transaction aligns with Novavax's strategy to evolve into a leaner and more focused organization. Completion of these acquisitions is expected by the end of 2024, subject to customary closing conditions and regulatory approvals.
Sectors
- Pharmaceuticals
- Manufacturing
Geography
- Europe – Represents the location of the Catalent manufacturing sites in Italy and Belgium, and regulatory oversight by the European Commission.
- United States – Home to one of the Catalent manufacturing sites in Bloomington, Indiana.
- Czech Republic – Site of Novavax's manufacturing facility being acquired by Novo Nordisk.
Industry
- Pharmaceuticals – This industry involves the manufacturing, production, and distribution of drugs and pharmaceutical products. The article details acquisitions by Novo Nordisk that expand its drug manufacturing facilities.
- Manufacturing – Focused on operations involved in the production processes of pharmaceuticals. The article discusses the acquisition of manufacturing sites in various countries.
Financials
- $11 billion – Amount paid by Novo Nordisk to acquire the three Catalent manufacturing sites.
- $200 million – Purchase price for Novavax's manufacturing facility in the Czech Republic by Novo Nordisk.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novo Nordisk | Acquirer | Company | A leading global healthcare company focused on drug manufacturing, particularly for diabetes and obesity. |
| Novo Holdings | Seller | Company | A holding and investment company managing the assets of the Novo Nordisk Foundation. |
| Catalent | Target Company | Company | A partner in drug development and manufacturing, providing services to biopharmaceutical companies. |
| Novavax | Target Company | Company | A biotechnology company selling its Czech manufacturing facility to streamline its operations and focus on its pipeline. |
| European Commission | Regulatory Authority | Government | Responsible for approving the acquisition of Catalent in this transaction. |